WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205948
Description: AZD-0424 is an orally bioavailable small molecule tyrosine kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Upon oral administration, AZD0424 selectively inhibits both Src and Abl kinase activity which may result in the inhibition of tumor growth in susceptible tumor cells. Src and Abl kinases are upregulated in certain tumor cells and play important roles in tumor cell proliferation and metastasis.
MedKoo Cat#: 205948
Chemical Formula: C25H29ClN6O5
Exact Mass: 528.1888
Molecular Weight: 528.994
Elemental Analysis: C, 56.76; H, 5.53; Cl, 6.70; N, 15.89; O, 15.12
AZD-0424, purity > 98%, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: AZD0424; AZD 0424; AZD-0424
IUPAC/Chemical Name: 1-(4-(2-((4-((6-chloro-[1,3]dioxolo[4,5-b]pyridin-7-yl)amino)-5-isopropoxyquinazolin-7-yl)oxy)ethyl)piperazin-1-yl)ethan-1-one
InChi Key: MVWATCATLSSVBH-UHFFFAOYSA-N
InChi Code: InChI=1S/C25H29ClN6O5/c1-15(2)37-20-11-17(34-9-8-31-4-6-32(7-5-31)16(3)33)10-19-21(20)24(29-13-28-19)30-22-18(26)12-27-25-23(22)35-14-36-25/h10-13,15H,4-9,14H2,1-3H3,(H,27,28,29,30)
SMILES Code: CC(C)OC1=C2C(N=CN=C2NC3=C(OCO4)C4=NC=C3Cl)=CC(OCCN5CCN(C(C)=O)CC5)=C1
The following data is based on the product molecular weight 528.994 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Nowak D, Boehrer S, Hochmuth S, Trepohl B, Hofmann W, Hoelzer D, Hofmann WK, Mitrou PS, Ruthardt M, Chow KU. Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells. Anticancer Drugs. 2007 Oct;18(9):981-95. PubMed PMID: 17704648.